Aeolus Pharmaceuticl (AOLS) 0.3150 $AOLS
Aeolus Receives Notice of Allowance From Israeli Patent Office for Use of AEOL 10150 and Other Aeolus Compounds to Treat Injury From Exposure to Alkylating Agents Such as Sulfur Mustard Gas
Marketwired - Tue Mar 31, 7:03AM CDT
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with significant funding from the US Government, announced today that it has received a Notice of Allowance from the Israeli Patent Office for application number 209435, "Methods for Treating Injury Associated with Exposure to an Alkylating Species." The patent covers Aeolus' lead compound, AEOL 10150 as well as other metalloporphyrins under development by the Company. Alkylating agents include chemical gas agents such as sulfur mustard gas.
Aeolus wins US FDA's orphan drug designation for AEOL 10150 for treating idiopathic pulmonary fibrosis
M2 - Wed Mar 18, 6:55AM CDT
Biotechnology company Aeolus Pharmaceuticals (OtherOTC:AOLS) reported on Tuesday the receipt of orphan drug designation for AEOL 10150 for treatment of idiopathic pulmonary fibrosis from from the Office of Orphan Products Development at the US Food & Drug Administration (FDA).
Aeolus Pharma antioxidant an Orphan Drug for lung disease
Seeking Alpha - at Seeking Alpha - Tue Mar 17, 12:38PM CDT
Aeolus Receives Orphan Drug Designation From US FDA for AEOL 10150 for Treatment of Idiopathic Pulmonary Fibrosis
Marketwired - Tue Mar 17, 10:46AM CDT
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with significant funding from the US Government, announced today that it has received notice from the Office of Orphan Products Development at the U.S. Food & Drug Administration (FDA) granting Orphan Drug Designation for AEOL 10150 "for treatment of idiopathic pulmonary fibrosis." Orphan Drug Designation entitles the sponsor to a seven-year marketing exclusivity period, clinical protocol assistance with the FDA, as well as federal grants and tax credits.
Aeolus' Q1 fiscal 2015 net loss widens to USD698,000
M2 - Mon Feb 16, 3:00AM CST
Biotechnology company Aeolus Pharmaceuticals (Other OTC:AOLS) stated on Friday that it recorded a net loss of USD698,000 (USD0.01 per share) for the three months ended 31 December 2014.
Aeolus Announces First Quarter Fiscal Year 2015 Financial Results
Marketwired - Fri Feb 13, 4:42PM CST
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with significant funding from the US Government, announced today financial results for the three months ended December 31, 2014.
Pulmonary Fibrosis Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Mon Jan 26, 9:32AM CST
The report "Pulmonary Fibrosis - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Pulmonary Fibrosis. Pulmonary Fibrosis is a breathing disorder. It is caused primarily because of the Lung tissues getting damaged. The lung tissues are affected with scars and this leads to the overall respiratory problem. The patient has serious breathing problem if he is dealing with this disorder. The key issue that the body faces internally is that of lack of oxygen due to thickening of the walls. Since the oxygen supply is reduced the patient has serious issues respirating. Complete report is available at http://www.rnrmarketresearch.com/pulmonary-fi...eport.html .
BIIB: 425.65 (-0.98), PSTI: 2.81 (unch), ASPX: 100.58 (+0.10), LPTN: 2.49 (+0.18), IBIO: 0.90 (-0.15), FGEN: 29.90 (+0.06), AQXP: 8.47 (+0.22), GALT: 3.26 (+0.02), LLY: 73.92 (+1.56), BMY: 64.64 (+1.18), GSK: 48.23 (+0.51), GILD: 101.77 (+0.61), CGEN: 7.27 (+0.11), FPRX: 20.98 (+0.96), CELGZ: 2.89 (+0.04)
Aeolus Announces Response to FDA Clinical Hold and Plan for Clinical Development of AEOL 10150
Marketwired - Thu Jan 08, 7:31AM CST
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats in partnership with the US Government, announced today that it has filed a formal mitigation response to the Division of Medical Imaging Products ("DMIP"
of the U.S. Food and Drug Administration ("FDA" after consultation with its development partner, the Biomedical Advanced Research and Development Authority ("BARDA" . The response addresses the questions cited by the DMIP when it placed a clinical hold on the Investigational New Drug Application ("IND" for the testing of AEOL 10150 in healthy human volunteers in September 2014. The healthy volunteer safety studies are part of the Lung Acute Radiation Syndrome ("Lung-ARS" Medical Countermeasure ("MCM" program funded by BARDA under a five-year contract worth up to $118.4 million. BARDA is the division of the U.S. Department of Health and Human Services responsible for the advanced development of MCM for chemical, biological, radiological and nuclear threats.
Aeolus Pharmaceuticals to Present at OneMed Forum SF 2015 Conference
Marketwired - Tue Dec 30, 7:30AM CST
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats in partnership with the US Government, announced today that David C. Cavalier, Chairman and Chief Financial Officer, will present at the OneMed Forum SF 2015 Conference on Tuesday, January 13, 2015 at 10:50 AM PST (2:50 PM EST) at the Marriott Marquis in San Francisco.
Aeolus posts lower fiscal 2014 net loss of USD80,000
M2 - Tue Dec 23, 5:32AM CST
Biotechnology company Aeolus Pharmaceuticals (OtherOTC:AOLS) stated on Monday that its net loss was USD80,000 for the fiscal year ended 30 September 2014.
Aeolus Announces Fiscal Year 2014 Financial Results
Marketwired - Mon Dec 22, 4:16PM CST
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats in partnership with the US Government, announced today financial results for the three months and twelve months ended September 30, 2014.
Aeolus files international patent for AEOL 10150 covering synthesis, formulation and pharmaceutical composition
M2 - Thu Dec 04, 6:07AM CST
Biotechnology company Aeolus Pharmaceuticals (Other OTC:AOLS) disclosed on Wednesday that it has filed an international patent application under the Patent Cooperation Treaty (PCT) with the United States Receiving Office (US/RO) seeking protection in all PCT contracting countries for its lead compound, AEOL 10150.
Aeolus Files International Patent Application for New Patent on AEOL 10150
Marketwired - Wed Dec 03, 7:31AM CST
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)
Aeolus Pharmateucticals to Present at LD Micro Invitational Conference
Marketwired - Tue Dec 02, 10:31AM CST
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats in partnership with the US Government, announced today that John McManus, Chief Executive Officer, will present at the LD Micro Invitational Conference on Thursday, December 4th, 2014 at 9:00 AM PST (12:00 PM EST) at the Luxe Sunset Boulevard Hotel in Los Angeles. Mr. McManus will provide an overview of Aeolus' development programs with a focus on the Company's progress under its contract with the Biomedical Advanced Research and Development Authority ("BARDA" . The BARDA contract, worth up to $118.4 million, funds all development costs for the Company's lead compound, AEOL 10150, as a treatment for the pulmonary effects of acute radiation exposure ("Lung-ARS" following a nuclear event.
Aeolus Receives Notice of Allowance From Israeli Patent Office for Use of AEOL 10150 and Other Aeolus Compounds to Treat Injury From Exposure to Alkylating Agents Such as Sulfur Mustard Gas
Marketwired - Tue Mar 31, 7:03AM CDT
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with significant funding from the US Government, announced today that it has received a Notice of Allowance from the Israeli Patent Office for application number 209435, "Methods for Treating Injury Associated with Exposure to an Alkylating Species." The patent covers Aeolus' lead compound, AEOL 10150 as well as other metalloporphyrins under development by the Company. Alkylating agents include chemical gas agents such as sulfur mustard gas.
Aeolus wins US FDA's orphan drug designation for AEOL 10150 for treating idiopathic pulmonary fibrosis
M2 - Wed Mar 18, 6:55AM CDT
Biotechnology company Aeolus Pharmaceuticals (OtherOTC:AOLS) reported on Tuesday the receipt of orphan drug designation for AEOL 10150 for treatment of idiopathic pulmonary fibrosis from from the Office of Orphan Products Development at the US Food & Drug Administration (FDA).
Aeolus Pharma antioxidant an Orphan Drug for lung disease
Seeking Alpha - at Seeking Alpha - Tue Mar 17, 12:38PM CDT
Aeolus Receives Orphan Drug Designation From US FDA for AEOL 10150 for Treatment of Idiopathic Pulmonary Fibrosis
Marketwired - Tue Mar 17, 10:46AM CDT
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with significant funding from the US Government, announced today that it has received notice from the Office of Orphan Products Development at the U.S. Food & Drug Administration (FDA) granting Orphan Drug Designation for AEOL 10150 "for treatment of idiopathic pulmonary fibrosis." Orphan Drug Designation entitles the sponsor to a seven-year marketing exclusivity period, clinical protocol assistance with the FDA, as well as federal grants and tax credits.
Aeolus' Q1 fiscal 2015 net loss widens to USD698,000
M2 - Mon Feb 16, 3:00AM CST
Biotechnology company Aeolus Pharmaceuticals (Other OTC:AOLS) stated on Friday that it recorded a net loss of USD698,000 (USD0.01 per share) for the three months ended 31 December 2014.
Aeolus Announces First Quarter Fiscal Year 2015 Financial Results
Marketwired - Fri Feb 13, 4:42PM CST
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with significant funding from the US Government, announced today financial results for the three months ended December 31, 2014.
Pulmonary Fibrosis Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Mon Jan 26, 9:32AM CST
The report "Pulmonary Fibrosis - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Pulmonary Fibrosis. Pulmonary Fibrosis is a breathing disorder. It is caused primarily because of the Lung tissues getting damaged. The lung tissues are affected with scars and this leads to the overall respiratory problem. The patient has serious breathing problem if he is dealing with this disorder. The key issue that the body faces internally is that of lack of oxygen due to thickening of the walls. Since the oxygen supply is reduced the patient has serious issues respirating. Complete report is available at http://www.rnrmarketresearch.com/pulmonary-fi...eport.html .
BIIB: 425.65 (-0.98), PSTI: 2.81 (unch), ASPX: 100.58 (+0.10), LPTN: 2.49 (+0.18), IBIO: 0.90 (-0.15), FGEN: 29.90 (+0.06), AQXP: 8.47 (+0.22), GALT: 3.26 (+0.02), LLY: 73.92 (+1.56), BMY: 64.64 (+1.18), GSK: 48.23 (+0.51), GILD: 101.77 (+0.61), CGEN: 7.27 (+0.11), FPRX: 20.98 (+0.96), CELGZ: 2.89 (+0.04)
Aeolus Announces Response to FDA Clinical Hold and Plan for Clinical Development of AEOL 10150
Marketwired - Thu Jan 08, 7:31AM CST
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats in partnership with the US Government, announced today that it has filed a formal mitigation response to the Division of Medical Imaging Products ("DMIP"
of the U.S. Food and Drug Administration ("FDA" after consultation with its development partner, the Biomedical Advanced Research and Development Authority ("BARDA" . The response addresses the questions cited by the DMIP when it placed a clinical hold on the Investigational New Drug Application ("IND" for the testing of AEOL 10150 in healthy human volunteers in September 2014. The healthy volunteer safety studies are part of the Lung Acute Radiation Syndrome ("Lung-ARS" Medical Countermeasure ("MCM" program funded by BARDA under a five-year contract worth up to $118.4 million. BARDA is the division of the U.S. Department of Health and Human Services responsible for the advanced development of MCM for chemical, biological, radiological and nuclear threats. Aeolus Pharmaceuticals to Present at OneMed Forum SF 2015 Conference
Marketwired - Tue Dec 30, 7:30AM CST
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats in partnership with the US Government, announced today that David C. Cavalier, Chairman and Chief Financial Officer, will present at the OneMed Forum SF 2015 Conference on Tuesday, January 13, 2015 at 10:50 AM PST (2:50 PM EST) at the Marriott Marquis in San Francisco.
Aeolus posts lower fiscal 2014 net loss of USD80,000
M2 - Tue Dec 23, 5:32AM CST
Biotechnology company Aeolus Pharmaceuticals (OtherOTC:AOLS) stated on Monday that its net loss was USD80,000 for the fiscal year ended 30 September 2014.
Aeolus Announces Fiscal Year 2014 Financial Results
Marketwired - Mon Dec 22, 4:16PM CST
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats in partnership with the US Government, announced today financial results for the three months and twelve months ended September 30, 2014.
Aeolus files international patent for AEOL 10150 covering synthesis, formulation and pharmaceutical composition
M2 - Thu Dec 04, 6:07AM CST
Biotechnology company Aeolus Pharmaceuticals (Other OTC:AOLS) disclosed on Wednesday that it has filed an international patent application under the Patent Cooperation Treaty (PCT) with the United States Receiving Office (US/RO) seeking protection in all PCT contracting countries for its lead compound, AEOL 10150.
Aeolus Files International Patent Application for New Patent on AEOL 10150
Marketwired - Wed Dec 03, 7:31AM CST
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)
Aeolus Pharmateucticals to Present at LD Micro Invitational Conference
Marketwired - Tue Dec 02, 10:31AM CST
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats in partnership with the US Government, announced today that John McManus, Chief Executive Officer, will present at the LD Micro Invitational Conference on Thursday, December 4th, 2014 at 9:00 AM PST (12:00 PM EST) at the Luxe Sunset Boulevard Hotel in Los Angeles. Mr. McManus will provide an overview of Aeolus' development programs with a focus on the Company's progress under its contract with the Biomedical Advanced Research and Development Authority ("BARDA"
. The BARDA contract, worth up to $118.4 million, funds all development costs for the Company's lead compound, AEOL 10150, as a treatment for the pulmonary effects of acute radiation exposure ("Lung-ARS" following a nuclear event. 
